Stem definition | Drug id | CAS RN |
---|---|---|
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives | 512 | 154-93-8 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 3.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.55 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 11.50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 78 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.23 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.37 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 7, 1977 | FDA | EMCURE PHARMS LTD |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myelodysplastic syndrome | 255.08 | 38.04 | 73 | 2722 | 15059 | 50587270 |
Malignant transformation | 139.60 | 38.04 | 23 | 2772 | 333 | 50601996 |
Brain oedema | 127.85 | 38.04 | 41 | 2754 | 12329 | 50590000 |
Febrile neutropenia | 115.57 | 38.04 | 70 | 2725 | 97597 | 50504732 |
Haematotoxicity | 114.75 | 38.04 | 34 | 2761 | 7861 | 50594468 |
Mucosal inflammation | 111.56 | 38.04 | 51 | 2744 | 40091 | 50562238 |
Acute myeloid leukaemia | 104.45 | 38.04 | 37 | 2758 | 15037 | 50587292 |
Stem cell transplant | 82.41 | 38.04 | 19 | 2776 | 1649 | 50600680 |
Second primary malignancy | 75.86 | 38.04 | 24 | 2771 | 6890 | 50595439 |
Thrombocytopenia | 69.62 | 38.04 | 57 | 2738 | 127616 | 50474713 |
Pneumocephalus | 61.26 | 38.04 | 10 | 2785 | 136 | 50602193 |
Enterococcal infection | 55.72 | 38.04 | 19 | 2776 | 6879 | 50595450 |
Venoocclusive disease | 54.68 | 38.04 | 14 | 2781 | 1882 | 50600447 |
Progressive multifocal leukoencephalopathy | 49.77 | 38.04 | 20 | 2775 | 11437 | 50590892 |
Intracranial hypotension | 48.86 | 38.04 | 9 | 2786 | 255 | 50602074 |
Chronic myelomonocytic leukaemia | 47.62 | 38.04 | 9 | 2786 | 294 | 50602035 |
Cardiomyopathy acute | 44.66 | 38.04 | 8 | 2787 | 193 | 50602136 |
Bacteraemia | 42.11 | 38.04 | 19 | 2776 | 14414 | 50587915 |
Pneumocystis jirovecii pneumonia | 41.82 | 38.04 | 19 | 2776 | 14644 | 50587685 |
Aplasia | 40.84 | 38.04 | 13 | 2782 | 3800 | 50598529 |
Neutropenia | 40.18 | 38.04 | 45 | 2750 | 147920 | 50454409 |
Febrile bone marrow aplasia | 38.08 | 38.04 | 14 | 2781 | 6297 | 50596032 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myelodysplastic syndrome | 339.73 | 32.72 | 125 | 5109 | 17669 | 29551624 |
Venoocclusive liver disease | 239.53 | 32.72 | 76 | 5158 | 6841 | 29562452 |
Malignant transformation | 218.48 | 32.72 | 46 | 5188 | 788 | 29568505 |
Acute myeloid leukaemia | 208.43 | 32.72 | 86 | 5148 | 16427 | 29552866 |
Febrile neutropenia | 183.00 | 32.72 | 154 | 5080 | 112086 | 29457207 |
Second primary malignancy | 134.72 | 32.72 | 49 | 5185 | 6656 | 29562637 |
Brain oedema | 122.17 | 32.72 | 54 | 5180 | 12166 | 29557127 |
Pneumocephalus | 113.65 | 32.72 | 19 | 5215 | 81 | 29569212 |
Off label use | 110.72 | 32.72 | 193 | 5041 | 300607 | 29268686 |
Blood stem cell transplant failure | 86.53 | 32.72 | 19 | 5215 | 399 | 29568894 |
Basal cell carcinoma | 77.43 | 32.72 | 44 | 5190 | 16866 | 29552427 |
Mucosal inflammation | 74.27 | 32.72 | 54 | 5180 | 31541 | 29537752 |
Venoocclusive disease | 71.98 | 32.72 | 24 | 5210 | 2515 | 29566778 |
Aspergillus infection | 69.46 | 32.72 | 35 | 5199 | 10546 | 29558747 |
Myositis | 61.65 | 32.72 | 32 | 5202 | 10251 | 29559042 |
Febrile bone marrow aplasia | 59.30 | 32.72 | 28 | 5206 | 7323 | 29561970 |
Transformation to acute myeloid leukaemia | 57.20 | 32.72 | 15 | 5219 | 680 | 29568613 |
Malignant neoplasm progression | 55.85 | 32.72 | 67 | 5167 | 73792 | 29495501 |
Bronchopulmonary aspergillosis | 53.49 | 32.72 | 31 | 5203 | 12313 | 29556980 |
Stem cell transplant | 53.22 | 32.72 | 18 | 5216 | 1969 | 29567324 |
Hepatic infection fungal | 52.91 | 32.72 | 11 | 5223 | 176 | 29569117 |
Neutropenic sepsis | 49.62 | 32.72 | 29 | 5205 | 11698 | 29557595 |
Product use in unapproved indication | 47.25 | 32.72 | 67 | 5167 | 86808 | 29482485 |
Metastases to muscle | 45.49 | 32.72 | 10 | 5224 | 211 | 29569082 |
Metastases to retroperitoneum | 45.22 | 32.72 | 10 | 5224 | 217 | 29569076 |
Enteritis | 43.20 | 32.72 | 22 | 5212 | 6769 | 29562524 |
Human herpesvirus 8 infection | 40.76 | 32.72 | 12 | 5222 | 835 | 29568458 |
Metastases to spleen | 40.10 | 32.72 | 10 | 5224 | 370 | 29568923 |
Cytomegalovirus infection | 39.94 | 32.72 | 33 | 5201 | 23182 | 29546111 |
B-cell lymphoma recurrent | 39.75 | 32.72 | 11 | 5223 | 612 | 29568681 |
Expanded disability status scale score increased | 38.71 | 32.72 | 9 | 5225 | 246 | 29569047 |
Cytopenia | 38.10 | 32.72 | 23 | 5211 | 9836 | 29559457 |
Pancytopenia | 37.82 | 32.72 | 59 | 5175 | 83109 | 29486184 |
Metastases to bone marrow | 37.74 | 32.72 | 10 | 5224 | 472 | 29568821 |
Intracranial hypotension | 34.68 | 32.72 | 8 | 5226 | 211 | 29569082 |
Retinal haemorrhage | 32.81 | 32.72 | 16 | 5218 | 4488 | 29564805 |
Intentional product use issue | 32.80 | 32.72 | 39 | 5195 | 42459 | 29526834 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myelodysplastic syndrome | 544.00 | 30.53 | 178 | 7246 | 27401 | 64463907 |
Malignant transformation | 332.50 | 30.53 | 64 | 7360 | 1077 | 64490231 |
Acute myeloid leukaemia | 313.19 | 30.53 | 118 | 7306 | 27345 | 64463963 |
Febrile neutropenia | 293.95 | 30.53 | 211 | 7213 | 187446 | 64303862 |
Venoocclusive liver disease | 256.52 | 30.53 | 79 | 7345 | 9936 | 64481372 |
Brain oedema | 223.43 | 30.53 | 87 | 7337 | 21988 | 64469320 |
Second primary malignancy | 204.59 | 30.53 | 70 | 7354 | 12267 | 64479041 |
Pneumocephalus | 144.75 | 30.53 | 25 | 7399 | 220 | 64491088 |
Mucosal inflammation | 134.88 | 30.53 | 86 | 7338 | 62498 | 64428810 |
Haematotoxicity | 134.58 | 30.53 | 52 | 7372 | 12844 | 64478464 |
Stem cell transplant | 121.93 | 30.53 | 35 | 7389 | 3446 | 64487862 |
Off label use | 114.91 | 30.53 | 235 | 7189 | 632571 | 63858737 |
Venoocclusive disease | 108.64 | 30.53 | 33 | 7391 | 3952 | 64487356 |
Blood stem cell transplant failure | 89.99 | 30.53 | 19 | 7405 | 516 | 64490792 |
Aspergillus infection | 75.11 | 30.53 | 37 | 7387 | 16342 | 64474966 |
Pneumocystis jirovecii pneumonia | 72.26 | 30.53 | 43 | 7381 | 27591 | 64463717 |
Malignant neoplasm progression | 67.99 | 30.53 | 74 | 7350 | 112797 | 64378511 |
Basal cell carcinoma | 67.91 | 30.53 | 43 | 7381 | 30795 | 64460513 |
Febrile bone marrow aplasia | 65.62 | 30.53 | 30 | 7394 | 11225 | 64480083 |
Thrombocytopenia | 64.52 | 30.53 | 102 | 7322 | 223699 | 64267609 |
Cytomegalovirus infection | 62.90 | 30.53 | 44 | 7380 | 37155 | 64454153 |
Product use in unapproved indication | 61.58 | 30.53 | 88 | 7336 | 176530 | 64314778 |
Myositis | 60.56 | 30.53 | 32 | 7392 | 16345 | 64474963 |
Bronchopulmonary aspergillosis | 58.68 | 30.53 | 33 | 7391 | 19052 | 64472256 |
Progressive multifocal leukoencephalopathy | 57.34 | 30.53 | 32 | 7392 | 18200 | 64473108 |
Aplasia | 55.07 | 30.53 | 23 | 7401 | 6930 | 64484378 |
Hemiplegia | 53.11 | 30.53 | 27 | 7397 | 12741 | 64478567 |
Pneumonia respiratory syncytial viral | 52.85 | 30.53 | 15 | 7409 | 1416 | 64489892 |
Intracranial hypotension | 50.57 | 30.53 | 11 | 7413 | 345 | 64490963 |
Neutropenic sepsis | 50.11 | 30.53 | 32 | 7392 | 23240 | 64468068 |
B-cell lymphoma recurrent | 46.07 | 30.53 | 12 | 7412 | 820 | 64490488 |
Metastases to muscle | 45.90 | 30.53 | 10 | 7414 | 316 | 64490992 |
Cytopenia | 45.53 | 30.53 | 26 | 7398 | 15445 | 64475863 |
Metastases to retroperitoneum | 44.56 | 30.53 | 10 | 7414 | 363 | 64490945 |
Human herpesvirus 8 infection | 43.05 | 30.53 | 12 | 7412 | 1061 | 64490247 |
Lymphopenia | 42.55 | 30.53 | 30 | 7394 | 25627 | 64465681 |
Metastases to spleen | 41.52 | 30.53 | 10 | 7414 | 496 | 64490812 |
Conjunctival haemorrhage | 41.08 | 30.53 | 17 | 7407 | 5004 | 64486304 |
Pancytopenia | 40.79 | 30.53 | 65 | 7359 | 143244 | 64348064 |
Brain abscess | 40.56 | 30.53 | 16 | 7408 | 4165 | 64487143 |
Enterococcal infection | 39.99 | 30.53 | 23 | 7401 | 13843 | 64477465 |
Arthralgia | 39.57 | 30.53 | 3 | 7421 | 442257 | 64049051 |
Acute respiratory distress syndrome | 39.44 | 30.53 | 34 | 7390 | 38901 | 64452407 |
Metastases to bone marrow | 38.76 | 30.53 | 10 | 7414 | 658 | 64490650 |
Hepatic infection fungal | 38.68 | 30.53 | 8 | 7416 | 196 | 64491112 |
Neutropenia | 38.47 | 30.53 | 85 | 7339 | 239539 | 64251769 |
Enteritis | 37.43 | 30.53 | 21 | 7403 | 12056 | 64479252 |
Cardiomyopathy acute | 37.31 | 30.53 | 8 | 7416 | 234 | 64491074 |
Transformation to acute myeloid leukaemia | 36.25 | 30.53 | 10 | 7414 | 851 | 64490457 |
Staphylococcal infection | 35.41 | 30.53 | 36 | 7388 | 50642 | 64440666 |
Fatigue | 34.42 | 30.53 | 22 | 7402 | 748708 | 63742600 |
Respiratory tract infection fungal | 33.90 | 30.53 | 10 | 7414 | 1082 | 64490226 |
Cystitis haemorrhagic | 33.59 | 30.53 | 17 | 7407 | 7939 | 64483369 |
Dizziness | 33.18 | 30.53 | 5 | 7419 | 430158 | 64061150 |
Chronic myelomonocytic leukaemia | 32.85 | 30.53 | 9 | 7415 | 746 | 64490562 |
Human herpesvirus 6 infection | 32.23 | 30.53 | 14 | 7410 | 4640 | 64486668 |
Implant site oedema | 32.11 | 30.53 | 5 | 7419 | 21 | 64491287 |
Malaise | 31.99 | 30.53 | 4 | 7420 | 396243 | 64095065 |
Expanded disability status scale score increased | 31.96 | 30.53 | 8 | 7416 | 466 | 64490842 |
Myelosuppression | 30.83 | 30.53 | 24 | 7400 | 23806 | 64467502 |
Herpes simplex reactivation | 30.78 | 30.53 | 7 | 7417 | 270 | 64491038 |
None
Source | Code | Description |
---|---|---|
ATC | L01AD01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrosoureas |
FDA MoA | N0000000236 | Alkylating Activity |
FDA EPC | N0000175558 | Alkylating Drug |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
MeSH PA | D000477 | Alkylating Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
MeSH PA | D009676 | Noxae |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Glioma, malignant | indication | 74532006 | |
Diffuse non-Hodgkin's lymphoma, large cell | indication | 109969005 | |
Multiple myeloma | indication | 109989006 | DOID:9538 |
Hodgkin's disease | indication | 118599009 | |
Non-Hodgkin's lymphoma | indication | 118601006 | |
Glioblastoma multiforme of brain | indication | 276828006 | DOID:3073 |
Malignant neoplasm of brain | indication | 428061005 | DOID:1319 |
Astrocytoma, anaplastic | off-label use | 55353007 | DOID:3078 |
Allogeneic bone marrow transplantation | off-label use | 58390007 | |
Mycosis fungoides | off-label use | 118618005 | |
Cerebral edema | contraindication | 2032001 | |
Mycosis | contraindication | 3218000 | DOID:1564 |
Meningitis | contraindication | 7180009 | DOID:9471 |
Disorder of lung | contraindication | 19829001 | DOID:850 |
Retinal hemorrhage | contraindication | 28998008 | |
Viral disease | contraindication | 34014006 | DOID:934 |
Infectious disease | contraindication | 40733004 | |
Fibrosis of lung | contraindication | 51615001 | DOID:3770 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Bacterial infectious disease | contraindication | 87628006 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Acute leukemia, disease | contraindication | 91855006 | DOID:12603 |
Liver function tests abnormal | contraindication | 166603001 | |
Obstructive hydrocephalus | contraindication | 230746009 | DOID:14159 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Abscess of brain | contraindication | 441806004 | |
Protozoal Infection | contraindication | ||
Significant Bleeding | contraindication | ||
Pulmonary Infiltrates | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.09 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glutathione reductase, mitochondrial | Enzyme | INHIBITOR | IC50 | 5.09 | CHEMBL | CHEMBL |
ID | Source |
---|---|
4020993 | VUID |
N0000148463 | NUI |
D00254 | KEGG_DRUG |
2105 | RXNORM |
4018136 | VANDF |
4020993 | VANDF |
C0007257 | UMLSCUI |
CHEBI:3423 | CHEBI |
CHEMBL513 | ChEMBL_ID |
DB00262 | DRUGBANK_ID |
D002330 | MESH_DESCRIPTOR_UI |
2578 | PUBCHEM_CID |
2959 | INN_ID |
6800 | IUPHAR_LIGAND_ID |
U68WG3173Y | UNII |
251354 | MMSL |
4360 | MMSL |
d01342 | MMSL |
002640 | NDDF |
387281007 | SNOMEDCT_US |
51326002 | SNOMEDCT_US |
786790001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Gliadel | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24338-050 | WAFER | 7.70 mg | INTRACAVITARY | NDA | 25 sections |